Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 6/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23329665 | 0.79 | AOC2 (0.50) | AOC2MAOALMNAGAACA2 | |
| SCHEMBL23370133 | 0.76 | AOC2 (0.62) | AOC2ALDH1A1MAOACA2MAOB | |
| SCHEMBL23358643 | 0.76 | AOC2 (1.00) | AOC2MAOAMAOB | |
| SCHEMBL23358641 | 0.76 | AOC2 (1.00) | AOC2MAOAMAOB | |
| SCHEMBL23370120 | 0.75 | AOC2 (0.55) | AOC2ALDH1A1LMNAGAACA2 | |
| SCHEMBL10250701 | 0.74 | AOC2 (0.46) | AOC2LMNAGAA | |
| SCHEMBL23370237 | 0.72 | AOC2 (0.64) | AOC2ALDH1A1MAOACA2CYP2C19 | |
| SCHEMBL10130720 | 0.68 | AOC2 (0.37) | AOC2ALDH1A1GAAMAOB | |
| SCHEMBL22387991 | 0.67 | PIK3CD (0.53) | AOC2ALDH1A1GAA | |
| SCHEMBL21740018 | 0.67 | AOC2 (0.36) | AOC2ALDH1A1GAAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | ECCOGENE INC. | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026801-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885KDM4E 4651/4885ALDH1A1 471/4885 |
| US-20210147360-A1 | SSAO INHIBITORS AND USE THEREOF | SSB, HAO1, SORD | AOC2 39/4885KDM4E 4651/4885ALDH1A1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.